Your Sleep Ring Is Decent on Hours and Heart Rate, Shaky on Sleep Stages. Its Maker’s IPO Filing Flags the Risk
A Journal columnist took her Oura ring into Stanford’s sleep lab to learn which numbers hold up. Now the $11 billion ring maker is heading for an IPO, and a retail broker has a seat in the deal.
By Sean Anees Saifi · Capital Wealth · Published Thursday, September 10, 2026 · Source: The Wall Street Journal, September 8 and 10, 2026 editions (Personal Journal)
Key Points
Oura, the smart-ring maker expected to be valued above $11 billion, filed for its IPO on Sept. 3, and its own S-1 warns that unreliable metrics could hurt its reputation.
A proposed class action says the ring failed to track a buyer’s sleep accurately; consumer trackers infer sleep from movement, pulse and skin temperature rather than brain waves.
Oura’s 95% accuracy claim covers only telling sleep from wakefulness; on sleep stages its own data show 76%–79% agreement with a clinical study, and a 2025 Nature study of 45 people found 53%.
Experts rank total sleep time and consistent bed and wake times as most trustworthy, resting heart rate as fairly reliable and sleep stages as a tossup — and human sleep technicians disagree by up to 20%.
Robinhood Markets (HOOD) is listed 18th of 18 underwriters in its first formal underwriting role, and its venture fund owns a stake in Oura; in Robinhood’s own 2021 IPO, about 25% of shares went to its users, versus a typical 10%.
95%
Oura’s accuracy claim: sleep vs. wake only
53%
sleep-stage agreement, 2025 Nature study
$11B+
Oura’s expected valuation in its IPO
18th
Robinhood’s slot among 18 underwriters
Consumer sleep trackers estimate sleep from movement, pulse and skin temperature rather than the brain waves a clinical sleep study records.
In one line: Trust a sleep ring’s trends, not its nightly scores — and judge its maker’s hot IPO the same way, on what it can actually measure.
Nicole Nguyen’s Oura ring once counted a motionless binge-watching session as sleep. That’s the whole problem in miniature: consumer trackers don’t read brain waves. They infer sleep from movement, pulse and skin temperature, so a very still viewer can pass for a very sound sleeper. Yet when Nguyen, the Journal’s personal-tech columnist, joined an overnight study in Stanford’s sleep lab, the same ring matched the clinic’s equipment on resting heart rate. So which numbers deserve your trust — and, now that Oura is heading for an IPO, which deserve your money?
What the ring actually knows
Oura’s 95% accuracy claim covers one job: telling sleep from wakefulness. On the four sleep stages, agreement drops. Oura’s own data show 76% to 79% agreement with a clinical sleep study; a 2025 Nature study of 45 people found 53%, which Oura attributes to older hardware and fit issues. Then again, Stanford’s Rafael Pelayo notes that human sleep technicians can disagree by up to 20%. The experts’ ranking: total sleep time and consistent bed and wake times are the most trustworthy numbers; resting heart rate is fairly reliable, less so when you’re moving or on darker skin; sleep stages are a tossup. Pelayo compares a tracker to a bathroom scale, useful for trends as long as it’s always the same scale. Read weeks, not nightly scores, and if the numbers start making you anxious, stop tracking. Doctors call that anxiety orthosomnia.
Same test for the prospectus
Here’s the twist. Oura filed for its IPO on Sept. 3 and is expected to be valued above $11 billion, just as a proposed class action claims its ring failed to track a buyer’s sleep accurately. Its own S-1 warns that unreliable metrics could hurt its reputation. Robinhood Markets (HOOD) is listed 18th and last among the underwriters, its first formal role since winning regulatory approval in June, and that seat could give it more say over how many shares reach individual investors, who usually get whatever institutions leave. The ties are cozy: Robinhood’s venture fund owns a stake in Oura, and Robinhood’s former CFO sits on Oura’s board.
A hot consumer IPO is a lottery ticket with a prospectus stapled to it, and the model portfolios don’t buy lottery tickets. That’s not a knock on the ring — health data can be genuinely useful — just a rule about judging things by what they can actually measure. The ring earns trust on hours and heart rate, over weeks. A new stock earns it the same way: on results you can read, over quarters, not on the buzz of its first day. If an offer to request shares pops up in your app, bring it to your next review before you tap. Anything you commit should be money you could lose without losing sleep. The ring will let you know, roughly.
What It Means For Your Portfolio
Avoid — a hot consumer IPO is a lottery ticket, not a plan
Health data earns its keep in trends — total sleep, steady bedtimes, resting heart rate — and a hot IPO deserves the same test: judge it on what it can actually measure, and keep any lottery-ticket money small enough to lose.
General planning principles, not advice for anyone in particular: an IPO allocation offered through an app is still a concentrated bet on a single company, and individual investors usually get whatever institutions leave. Read the risk factors before the story, size any speculative position so a total loss wouldn’t dent the plan, and read wearable data the way doctors do — weekly trends, not nightly scores.
In the book, there’s no Oura position and no plan to chase the offering; hot IPO allocations are the kind of lottery ticket the model portfolios avoid, however good the brand’s buzz. Nothing new is being bought ahead of Friday’s inflation report, and any future look at a newly listed company would start with reported results, not first-day demand.
